What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

December 8, 2025BloodOpen Access

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)

View Full Paper

Ask AI

Bookmark

Authors

BKBradley KievitNew York City Department of Health and Mental Hygiene RBRob BlissettNew York City Department of Health and Mental Hygiene HHHil HsuGilead Sciences (Australia)

Discussion

Member takes

Implication

Simulation analysis shows adherence to NCCN guidelines improves overall survival in R/R DLBCL with CAR T-cell therapy, highlighting treatment misallocation implications.

Key Points

Patients not receiving CAR T-cell therapy had a predicted overall survival rate of 42% after receiving non-recommended treatments.
Projected data indicates that 75% misallocation in treatment pathways leads to 783 additional deaths within five years.
Analysis utilized a patient-level simulation model to evaluate long-term survival outcomes in R/R DLBCL patients.
Findings stress the necessity of adhering to NCCN guidelines to enhance survival outcomes for CAR T-eligible patients.

Cite This Study

Kievit et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d9 https://doi.org/10.1182/blood-2025-4510

View Full Paper

Ask AI

Bookmark

Implication

Simulation analysis shows adherence to NCCN guidelines improves overall survival in R/R DLBCL with CAR T-cell therapy, highlighting treatment misallocation implications.

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Discussion

Member takes

Implication

Key Points

Cite This Study

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider